Literature DB >> 10448070

Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation.

H Murakami1, T Iwashita, N Asai, Y Shimono, Y Iwata, K Kawai, M Takahashi.   

Abstract

We compared the intracellular signalling pathways through Ret tyrosine kinase activated by glial cell line-derived neurotrophic factor (GDNF), multiple endocrine neoplasia (MEN) 2A, or MEN 2B mutation. Tyrosine phosphorylation of Grb2-associated binder-1 (Gab1) and activation of phosphatidylinositol 3-kinase (PI 3-kinase) were induced at higher levels by GDNF stimulation or the MEN 2B mutation than by the MEN 2A mutation. Tyrosine-phosphorylated Gab1 was a major component that interacted with the active PI 3-kinase in vivo. In addition, we found that p62Dok and PKB/Akt were phosphorylated in a PI 3-kinase-dependent manner and the levels of their phosphorylation were significantly higher in the MEN 2B transfectant than in the MEN 2A transfectant. Tyrosine phosphorylation of p62Dok resulted in its complex formation with the Ras GTPase-activating protein (RasGAP) and the Nck adaptor protein. These findings thus suggested that high levels of activation of PI 3-kinase and of phosphorylation of its downstream signalling molecules may be associated with the clinical phenotype of MEN 2B. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10448070     DOI: 10.1006/bbrc.1999.1186

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  20 in total

1.  Role of Gab1 in heart, placenta, and skin development and growth factor- and cytokine-induced extracellular signal-regulated kinase mitogen-activated protein kinase activation.

Authors:  M Itoh; Y Yoshida; K Nishida; M Narimatsu; M Hibi; T Hirano
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

2.  A Drosophila model of multiple endocrine neoplasia type 2.

Authors:  Renee D Read; Paul J Goodfellow; Elaine R Mardis; Nancy Novak; Jon R Armstrong; Ross L Cagan
Journal:  Genetics       Date:  2005-06-18       Impact factor: 4.562

Review 3.  Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.

Authors:  Alexander Drilon; Zishuo I Hu; Gillianne G Y Lai; Daniel S W Tan
Journal:  Nat Rev Clin Oncol       Date:  2017-11-14       Impact factor: 66.675

Review 4.  Thyroid Cancer: Role of RET and Beyond.

Authors:  Francesca Carlomagno
Journal:  Eur Thyroid J       Date:  2012-03-28

5.  C-cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B.

Authors:  C L Smith-Hicks; K C Sizer; J F Powers; A S Tischler; F Costantini
Journal:  EMBO J       Date:  2000-02-15       Impact factor: 11.598

Review 6.  Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis.

Authors:  J R Hansford; L M Mulligan
Journal:  J Med Genet       Date:  2000-11       Impact factor: 6.318

Review 7.  Central role of RET in thyroid cancer.

Authors:  Massimo Santoro; Francesca Carlomagno
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

8.  Characterization of gene expression induced by RET with MEN2A or MEN2B mutation.

Authors:  Tsuyoshi Watanabe; Masatoshi Ichihara; Mizuo Hashimoto; Keiko Shimono; Yoshie Shimoyama; Tetsuro Nagasaka; Yoshiki Murakumo; Hideki Murakami; Hideshi Sugiura; Hisashi Iwata; Naoki Ishiguro; Masahide Takahashi
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

Review 9.  Prophylactic thyroidectomy in multiple endocrine neoplasia: the impact of molecular mechanisms of RET proto-oncogene.

Authors:  Andrea Frilling; Frank Weber; Carsten Tecklenborg; Christoph Erich Broelsch
Journal:  Langenbecks Arch Surg       Date:  2003-03-25       Impact factor: 3.445

Review 10.  Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs.

Authors:  Orly Weinreb; Silvia Mandel; Orit Bar-Am; Merav Yogev-Falach; Yael Avramovich-Tirosh; Tamar Amit; Moussa B H Youdim
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.